Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Clinical Rheumatology
Published in: Clinical Rheumatology 4/2021

01-04-2021 | Idiopathic Pulmonary Fibrosis | Review Article

Rheumatoid arthritis–associated interstitial lung disease: an overview of epidemiology, pathogenesis and management

Authors: Yujie Dai, Weina Wang, Yikai Yu, Shaoxian Hu

Published in: Clinical Rheumatology | Issue 4/2021

Login to get access

Abstract

Interstitial lung disease (ILD) accounts for the major cause of morbidity and mortality in rheumatoid arthritis (RA). However, little is known of the pathogenesis, diagnosis and treatment of RA-associated ILD. In this review, we describe our present understanding and ongoing research in RA-ILD. Its aetiology does appear to associate with anti-cyclic citrullinated peptide antibodies, MUC5B mutation and smoking. Another focus of this article is on recent diagnostic methods in RA-ILD. Compared with other methods, high-resolution computed tomography (HRCT) imaging is a main method for the evaluation of ILD in RA patients. Pulmonary function is better suited for assessing progression. An important topic relates to therapeutic intervention. Disease-modifying anti-rheumatic drugs (DMARDs) in RA lack strong evidence in the onset or worsening of ILD. The available literature support that methotrexate, leflunomide, abatacept and rituximab play beneficial roles in the prevention and treatment of RA-ILD.
Literature
1.
2.
Lee HK, Kim DS, Yoo B, Seo JB, Rho JY, Colby TV, Kitaichi M (2005) Histopathologic pattern and clinical features of rheumatoid arthritis-associated interstitial lung disease. Chest 127:2019–2027PubMedCrossRef
3.
Suda T (2016) Up-to-date information on rheumatoid arthritis-associated interstitial lung disease. Clin Med Insights Circ Respir Pulm Med 9:155–162PubMedPubMedCentral
4.
Bongartz T, Nannini C, Medina-Velasquez YF, Achenbach SJ, Crowson CS, Ryu JH, Vassallo R, Gabriel SE, Matteson EL (2010) Incidence and mortality of interstitial lung disease in rheumatoid arthritis: a population-based study. Arthritis Rheum 62:1583–1591PubMedPubMedCentralCrossRef
5.
Turesson C, O'Fallon WM, Crowson CS, Gabriel SE, Matteson EL (2002) Occurrence of extraarticular disease manifestations is associated with excess mortality in a community based cohort of patients with rheumatoid arthritis. J Rheumatol 29:62–67PubMed
6.
Bilgici A, Ulusoy H, Kuru O, Çelenk Ç, Ünsal M, Danacı M (2005) Pulmonary involvement in rheumatoid arthritis. Rheumatol Int 25:429–435PubMedCrossRef
7.
Mori S, Cho I, Koga Y, Sugimoto M (2008) Comparison of pulmonary abnormalities on high-resolution computed tomography in patients with early versus longstanding rheumatoid arthritis. J Rheumatol 35:1513–1521PubMed
8.
Dawson JK, Fewins HE, Desmond J, Lynch MP, Graham DR (2001) Fibrosing alveolitis in patients with rheumatoid arthritis as assessed by high resolution computed tomography, chest radiography, and pulmonary function tests. Thorax 56:622–627PubMedPubMedCentralCrossRef
9.
Habib HM, Eisa AA, Arafat WR, Marie MA (2011) Pulmonary involvement in early rheumatoid arthritis patients. Clin Rheumatol 30:217–221PubMedCrossRef
10.
Gabbay E, Tarala R, Will R et al (1997) Interstitial lung disease in recent onset rheumatoid arthritis. Am J Respir Crit Care Med 156:528–535PubMedCrossRef
11.
Roos Ljungberg K, Joshua V, Skogh T et al. (2019) Secretory anti-citrullinated protein antibodies in serum associate with lung involvement in early rheumatoid arthritis. Rheumatology (Oxford)
12.
Robles-Perez A, Luburich P, Rodriguez-Sanchon B, Dorca J, Nolla JM, Molina-Molina M, Narvaez-Garcia J (2016) Preclinical lung disease in early rheumatoid arthritis. Chron Respir Dis 13:75–81PubMedPubMedCentralCrossRef
13.
Hyldgaard C, Hilberg O, Pedersen AB, Ulrichsen SP, Løkke A, Bendstrup E, Ellingsen T (2017) A population-based cohort study of rheumatoid arthritis-associated interstitial lung disease: comorbidity and mortality. Ann Rheum Dis 76:1700–1706PubMedCrossRef
14.
15.
Bongartz T, Cantaert T, Atkins SR, Harle P, Myers JL, Turesson C, Ryu JH, Baeten D, Matteson EL (2007) Citrullination in extra-articular manifestations of rheumatoid arthritis. Rheumatology 46:70–75PubMedCrossRef
16.
Paulin F, Doyle TJ, Fletcher EA, Ascherman DP, Rosas IO (2015) Rheumatoid arthritis-associated interstitial lung disease and idiopathic pulmonary fibrosis:shared mechanistic and phenotypic traits suggest overlapping disease mechanisms. Rev Investig Clin 67:280–286
17.
Ytterberg AJ, Joshua V, Reynisdottir G et al (2014) Shared immunological targets in the lungs and joints of patients with rheumatoid arthritis: identification and validation. Ann Rheum Dis 74:1772–1777PubMedCrossRef
18.
Correia CS, Briones MR, Guo R, Ostrowski RA (2019) Elevated anti-cyclic citrullinated peptide antibody titer is associated with increased risk for interstitial lung disease. Clin Rheumatol 38:1201–1206PubMedCrossRefPubMedCentral
19.
Jearn LH, Kim TY (2012) Level of anticitrullinated peptide/protein antibody is not associated with lung diseases in rheumatoid arthritis. J Rheumatol 39:1493–1494PubMedCrossRef
20.
Korkmaz C, Us T, Kasifoglu T et al (2006) Anti-cyclic citrullinated peptide [CCP] antibodies in patients with long-standing rheumatoid arthritis and their relationship with extra-articular manifestations. Clin Biochem 39:961–965PubMedCrossRef
21.
Inui N, Enomoto N, Suda T, Kageyama Y, Watanabe H, Chida K (2008) Anti-cyclic citrullinated peptide antibodies in lung diseases associated with rheumatoid arthritis. Clin Biochem 41:1074–1077PubMedCrossRef
22.
Zhu J, Zhou Y, Chen X, Li J (2014) A metaanalysis of the increased risk of rheumatoid arthritis-related pulmonary disease as a result of serum anticitrullinated protein antibody positivity. J Rheumatol 41:1282–1289PubMedCrossRef
23.
Young HW, Williams OW, Chandra D et al (2007) Central role of Muc5ac expression in mucous metaplasia and its regulation by conserved 5′ elements. Am J Respir Cell Mol Biol 37:273–290PubMedPubMedCentralCrossRef
24.
Juge PA, Lee JS, Ebstein E, Furukawa H, Dobrinskikh E, Gazal S, Kannengiesser C, Ottaviani S, Oka S, Tohma S, Tsuchiya N, Rojas-Serrano J, González-Pérez MI, Mejía M, Buendía-Roldán I, Falfán-Valencia R, Ambrocio-Ortiz E, Manali E, Papiris SA, Karageorgas T, Boumpas D, Antoniou K, van Moorsel CHM, van der Vis J, de Man YA, Grutters JC, Wang Y, Borie R, Wemeau-Stervinou L, Wallaert B, Flipo RM, Nunes H, Valeyre D, Saidenberg-Kermanac’h N, Boissier MC, Marchand-Adam S, Frazier A, Richette P, Allanore Y, Sibilia J, Dromer C, Richez C, Schaeverbeke T, Lioté H, Thabut G, Nathan N, Amselem S, Soubrier M, Cottin V, Clément A, Deane K, Walts AD, Fingerlin T, Fischer A, Ryu JH, Matteson EL, Niewold TB, Assayag D, Gross A, Wolters P, Schwarz MI, Holers M, Solomon JJ, Doyle T, Rosas IO, Blauwendraat C, Nalls MA, Debray MP, Boileau C, Crestani B, Schwartz DA, Dieudé P (2018) MUC5B promoter variant and rheumatoid arthritis with interstitial lung disease. N Engl J Med 379:2209–2219PubMedPubMedCentralCrossRef
25.
Helling BA, Gerber AN, Kadiyala V, Sasse SK, Pedersen BS, Sparks L, Nakano Y, Okamoto T, Evans CM, Yang IV, Schwartz DA (2017) Regulation of MUC5B expression in idiopathic pulmonary fibrosis. Am J Respir Cell Mol Biol 57:91–99PubMedPubMedCentralCrossRef
26.
Seibold MA, Wise AL, Speer MC, Steele MP, Brown KK, Loyd JE, Fingerlin TE, Zhang W, Gudmundsson G, Groshong SD, Evans CM, Garantziotis S, Adler KB, Dickey BF, du Bois RM, Yang IV, Herron A, Kervitsky D, Talbert JL, Markin C, Park J, Crews AL, Slifer SH, Auerbach S, Roy MG, Lin J, Hennessy CE, Schwarz MI, Schwartz DA (2011) A common MUC5B promoter polymorphism and pulmonary fibrosis. N Engl J Med 364:1503–1512PubMedPubMedCentralCrossRef
27.
28.
Juge PA, Borie R, Kannengiesser C et al (2017) Shared genetic predisposition in rheumatoid arthritis-interstitial lung disease and familial pulmonary fibrosis. Eur Respir J 49:1602314PubMedCrossRef
29.
Peljto AL, Zhang Y, Fingerlin TE, Ma SF, Garcia JGN, Richards TJ, Silveira LJ, Lindell KO, Steele MP, Loyd JE, Gibson KF, Seibold MA, Brown KK, Talbert JL, Markin C, Kossen K, Seiwert SD, Murphy E, Noth I, Schwarz MI, Kaminski N, Schwartz DA (2013) Association between the MUC5B promoter polymorphism and survival in patients with idiopathic pulmonary fibrosis. JAMA 309:2232–2239PubMedPubMedCentralCrossRef
30.
Adegunsoye A (2019) MUC5B promoter variant: genomic fingerprint for early identification of undiagnosed pulmonary fibrosis. Thorax 74:1111–1112PubMedCrossRef
31.
Charles PJ, Sweatman MC, Markwick JR, Maini RN (1991) HLA-B40: a marker for susceptibility to lung disease in rheumatoid arthritis. Dis Markers 9:97–101PubMed
32.
Scott TE, Wise RA, Hochberg MC, Wigley FM (1987) HLA-DR4 and pulmonary dysfunction in rheumatoid arthritis. Am J Med 82:765–771PubMedCrossRef
33.
Hillarby MC, McMahon MJ, Grennan DM et al (1993) HLA associations in subjects with rheumatoid arthritis and bronchiectasis but not with other pulmonary complications of rheumatoid disease. Br J Rheumatol 32:794–797PubMedCrossRef
34.
Sugiyama Y, Ohno S, Kano S et al (1994) Diffuse panbronchiolitis and rheumatoid arthritis: a possible correlation with HLA-B54. Intern Med 33:612–614PubMedCrossRef
35.
Gochuico BR, Avila NA, Chow CK, Novero LJ, Wu HP, Ren P, MacDonald S, Travis WD, Stylianou MP, Rosas IO (2008) Progressive preclinical interstitial lung disease in rheumatoid arthritis. Arch Intern Med 168:159–166PubMedCrossRef
36.
Albano SA, Santana-Sahagun E, Weisman MH (2001) Cigarette smoking and rheumatoid arthritis. Semin Arthritis Rheum 31:146–159PubMedCrossRef
37.
Matsuo T, Hashimoto M, Ito I, Kubo T, Uozumi R, Furu M, Ito H, Fujii T, Tanaka M, Terao C, Kono H, Mori M, Hamaguchi M, Yamamoto W, Ohmura K, Morita S, Mimori T (2019) Interleukin-18 is associated with the presence of interstitial lung disease in rheumatoid arthritis: a cross-sectional study. Scand J Rheumatol 48:87–94PubMedCrossRef
38.
Doyle TJ, Patel AS, Hatabu H, Nishino M, Wu G, Osorio JC, Golzarri MF, Traslosheros A, Chu SG, Frits ML, Iannaccone CK, Koontz D, Fuhrman C, Weinblatt ME, el-Chemaly SY, Washko GR, Hunninghake GM, Choi AMK, Dellaripa PF, Oddis CV, Shadick NA, Ascherman DP, Rosas IO (2015) Detection of rheumatoid arthritis-interstitial lung disease is enhanced by serum biomarkers. Am J Respir Crit Care Med 191:1403–1412PubMedPubMedCentralCrossRef
39.
40.
Zhang Y, Li H, Wu N, Dong X, Zheng Y (2017) Retrospective study of the clinical characteristics and risk factors of rheumatoid arthritis-associated interstitial lung disease. Clin Rheumatol 36:817–823PubMedCrossRef
41.
Assayag D, Elicker BM, Urbania TH, Colby TV, Kang BH, Ryu JH, King TE, Collard HR, Kim DS, Lee JS (2014) Rheumatoid arthritis-associated interstitial lung disease: radiologic identification of usual interstitial pneumonia pattern. Radiology 270:583–588PubMedPubMedCentralCrossRef
42.
Solomon JJ, Ryu JH, Tazelaar HD, Myers JL, Tuder R, Cool CD, Curran-Everett D, Fischer A, Swigris JJ, Brown KK (2013) Fibrosing interstitial pneumonia predicts survival in patients with rheumatoid arthritis-associated interstitial lung disease [RA-ILD]. Respir Med 107:1247–1252PubMedCrossRef
43.
Ascherman DP (2010) Interstitial lung disease in rheumatoid arthritis. Curr Rheumatol Rep 12:363–369PubMedCrossRef
44.
Kim EJ, Elicker BM, Maldonado F, Webb WR, Ryu JH, van Uden JH, Lee JS, King TE, Collard HR (2010) Usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease. Eur Respir J 35:1322–1132PubMedCrossRef
45.
Rajasekaran BA, Shovlin D, Lord P, Kelly CA (2001) Interstitial lung disease in patients with rheumatoid arthritis: a comparison with cryptogenic fibrosing alveolitis. Rheumatology (Oxford) 40:1022–1025CrossRef
46.
Travis WD, Costabel U, Hansell DM, King te Jr, Lynch DA, Nicholson AG, Ryerson CJ, Ryu JH, Selman M, Wells AU, Behr J, Bouros D, Brown KK, Colby TV, Collard HR, Cordeiro CR, Cottin V, Crestani B, Drent M, Dudden RF, Egan J, Flaherty K, Hogaboam C, Inoue Y, Johkoh T, Kim DS, Kitaichi M, Loyd J, Martinez FJ, Myers J, Protzko S, Raghu G, Richeldi L, Sverzellati N, Swigris J, Valeyre D, ATS/ERS Committee on Idiopathic Interstitial Pneumonias (2013) An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 188:733–748PubMedPubMedCentralCrossRef
47.
Katzenstein AL, Mukhopadhyay S, Myers JL (2008) Diagnosis of usual interstitial pneumonia and distinction from other fibrosing interstitial lung diseases. Hum Pathol 39:1562–1581PubMedCrossRef
48.
49.
Jacob J, Hirani N, van Moorsel CHM et al. (2019) Predicting outcomes in rheumatoid arthritis related interstitial lung disease. Eur Respir J 53(1)
50.
Caiulo VA, Gargani L, Caiulo S, Fisicaro A, Moramarco F, Latini G, Picano E (2011) Lung ultrasound in bronchiolitis: comparison with chest X-ray. Eur J Pediatr 170:1427–1433PubMedCrossRef
51.
Doveri M, Frassi F, Consensi A, Vesprini E, Gargani L, Tafuri M, Picano E, Della Rossa A, Delle Sedie A, d'Ascanio A, Giacomelli C, Bazzichi L, Bombardieri S (2008) Ultrasound lung comets: new echographic sign of lung interstitial fibrosis in systemic sclerosis. Reumatismo 60:180–184PubMed
52.
Mathis G, Gehmacher O (2001) Lung and pleural ultrasound. Praxis (Bern 1994) 90:681–686
53.
Volpicelli G, Elbarbary M, Blaivas M et al (2012) International evidence-based recommendations for point-of-care lung ultrasound. Intensive Care Med 38:577–591CrossRefPubMed
54.
Wohlgenannt S, Gehmacher O, Gehmacher U, Kopf A, Mathis G (2001) Sonographic findings in interstitial lung diseases. Ultraschall Med 22:27–31PubMedCrossRef
55.
Sperandeo M, Varriale A, Sperandeo G, Filabozzi P, Piattelli ML, Carnevale V, Decuzzi M, Vendemiale G (2009) Transthoracic ultrasound in the evaluation of pulmonary fibrosis: our experience. Ultrasound Med Biol 35:723–729PubMedCrossRef
56.
Moazedi-Fuerst FC, Kielhauser SM, Scheidl S et al (2014) Ultrasound screening for interstitial lung disease in rheumatoid arthritis. Clin Exp Rheumatol 32:199–203PubMed
57.
Solomon JJ, Chung JH, Cosgrove GP, Demoruelle MK, Fernandez-Perez ER, Fischer A, Frankel SK, Hobbs SB, Huie TJ, Ketzer J, Mannina A, Olson AL, Russell G, Tsuchiya Y, Yunt ZX, Zelarney PT, Brown KK, Swigris JJ (2016) Predictors of mortality in rheumatoid arthritis-associated interstitial lung disease. Eur Respir J 47:588–596PubMedCrossRef
58.
Ley B, Collard HR, King TE et al (2011) Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 183:431–440PubMedCrossRef
59.
Zamora-Legoff JA, Krause ML, Crowson CS, Ryu JH, Matteson EL (2017) Progressive decline of lung function in rheumatoid arthritis-associated interstitial lung disease. Arthritis Rheumatol 69:542–549PubMedPubMedCentralCrossRef
60.
Dawson JK, Fewins HE, Desmond J, Lynch MP, Graham DR (2002) Predictors of progression of HRCT diagnosed fibrosing alveolitis in patients with rheumatoid arthritis. Ann Rheum Dis 61:517–521PubMedPubMedCentralCrossRef
61.
Manfredi A, Cassone G, Cerri S et al (2019) Diagnostic accuracy of a velcro sound detector [VECTOR] for interstitial lung disease in rheumatoid arthritis patients: the InSPIRAtE validation study [INterStitial pneumonia in rheumatoid arthritis with an electronic device]. BMC Pulm Med 19:111PubMedPubMedCentralCrossRef
62.
Wu EK, Ambrosini RD, Kottmann RM et al. (2019) Reinterpreting evidence of rheumatoid arthritis-associated interstitial lung disease to understand etiology. Curr Rheumatol Rev
63.
Sparks JA, He X, Huang J, Fletcher EA, Zaccardelli A, Friedlander HM, Gill RR, Hatabu H, Nishino M, Murphy DJ, Iannaccone CK, Mahmoud TG, Frits ML, Lu B, Rosas IO, Dellaripa PF, Weinblatt ME, Karlson EW, Shadick NA, Doyle TJ (2019) Rheumatoid arthritis disease activity predicting incident clinically apparent rheumatoid arthritis-associated interstitial lung disease: a prospective cohort study. Arthritis Rheumatol 71:1472–1482PubMedPubMedCentralCrossRef
64.
Paulin F, Mercado JF, Fernández ME, Caro FM, Alberti ML, Fassola LA (2018) Correlation between lung and joint involvement in patients with rheumatoid arthritis and interstitial lung disease: a cross-sectional study. Rev Investig Clin 70:76–81
65.
Travis WD, Costabel U, Hansell DM, King te Jr, Lynch DA, Nicholson AG, Ryerson CJ, Ryu JH, Selman M, Wells AU, Behr J, Bouros D, Brown KK, Colby TV, Collard HR, Cordeiro CR, Cottin V, Crestani B, Drent M, Dudden RF, Egan J, Flaherty K, Hogaboam C, Inoue Y, Johkoh T, Kim DS, Kitaichi M, Loyd J, Martinez FJ, Myers J, Protzko S, Raghu G, Richeldi L, Sverzellati N, Swigris J, Valeyre D, ATS/ERS Committee on Idiopathic Interstitial Pneumonias (2013) ATS/ERS Committee on idiopathic interstitial pneumonias. An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 188:733–748PubMedPubMedCentralCrossRef
66.
Lake F, Proudman S (2014) Rheumatoid arthritis and lung disease: from mechanisms to a practical approach. Semin Respir Crit Care Med 35:222–238PubMedCrossRef
67.
Kelly C, Saravanan V (2008) Treatment strategies for a rheumatoid arthritis patient with interstitial lung disease. Expert Opin Pharmacother 9:3221–3230PubMedCrossRef
68.
Picchianti Diamanti A, Markovic M, Argento G, Giovagnoli S, Ricci A, Laganà B, D’Amelio R (2017) Therapeutic management of patients with rheumatoid arthritis and associated interstitial lung disease: case report and literature review. Ther Adv Respir Dis 11:64–72PubMedCrossRef
69.
Smolen JS, Landewe R, Breedveld FC et al (2014) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 73:492–509PubMedCrossRef
70.
Hozumi H, Nakamura Y, Johkoh T, Sumikawa H, Colby TV, Kono M, Hashimoto D, Enomoto N, Fujisawa T, Inui N, Suda T, Chida K (2013) Acute exacerbation in rheumatoid arthritis-associated interstitial lung disease: a retrospective case control study. BMJ Open 3:e003132PubMedPubMedCentralCrossRef
71.
McKendry RJ, Dale P (1993) Adverse effects of low dose methotrexate therapy in rheumatoid arthritis. J Rheumatol 20:1850–1856PubMed
72.
Hendrick DJ, Spickett GP (2005) Drug-induced lung disease. In: Oxford textbook of medicine, vol 2. Oxford University Press, Oxford, pp 1507–1512
73.
Conway R, Low C, Coughlan RJ, O'Donnell MJ, Carey JJ (2014) Methotrexate and lung disease in rheumatoid arthritis: a meta-analysis of randomized controlled trials. Arthritis Rheumatol 66:803–812PubMedCrossRef
74.
Kiely P, Busby AD, Nikiphorou E et al (2019) Is incident rheumatoid arthritis interstitial lung disease associated with methotrexate treatment? Results from a multivariate analysis in the ERAS and ERAN inception cohorts. BMJ Open 9:e028466PubMedPubMedCentralCrossRef
75.
Sawada T, Inokuma S, Sato T, Otsuka T, Saeki Y, Takeuchi T, Matsuda T, Takemura T, Sagawa A, on behalf of the Study Committee for Leflunomide-induced Lung Injury, Japan College of Rheumatology (2009) Leflunomide-induced interstitial lung disease:prevalence and risk factors in Japanese patients with rheumatoid arthritis. Rheumatology (Oxford) 48:1069–1072CrossRef
76.
Conway R, Low C, Coughlan RJ, O’Donnell MJ, Carey JJ (2016) Leflunomide use and risk of lung disease in rheumatoid arthritis: a systematic literature review and metaanalysis of randomized controlled trials. J Rheumatol 43:855–860PubMedCrossRef
77.
Perez-Alvarez R, Perez-de-Lis M, Diaz-Lagares C et al (2011) Interstitial lung disease induced or exacerbated by TNF-targeted therapies: analysis of 122 cases. Semin Arthritis Rheum 41:256Y26CrossRef
78.
Hadjinicolaou AV, Nisar MK, Bhagat S, Parfrey H, Chilvers ER, Ostor AJK (2011) Non-infectious pulmonary complications of newer biological agents for rheumatic diseases—a systematic literature review. Rheumatology (Oxford) 50:2297–2305CrossRef
79.
Pearce F, Johnson SR, Courtney P (2012) Interstitial lung disease following certolizumab pegol. Rheumatology (Oxford) 51:578–580CrossRef
80.
Koike T, Harigai M, Inokuma S, Ishiguro N, Ryu J, Takeuchi T, Takei S, Tanaka Y, Ito K, Yamanaka H (2011) Postmarketing surveillance of tocilizumab for rheumatoid arthritis in Japan: interim analysis of 3881 patients. Ann Rheum Dis 70:2148–2151PubMedCrossRef
81.
Kurata I, Tsuboi H, Terasaki M, Shimizu M, Toko H, Honda F, Ohyama A, Yagishita M, Osada A, Ebe H, Kawaguchi H, Takahashi H, Hagiwara S, Asashima H, Kondo Y, Matsumoto I, Sumida T (2019) Effect of biological disease-modifying anti-rheumatic drugs on airway and interstitial lung disease in patients with rheumatoid arthritis. Intern Med 58:1703–1712PubMedPubMedCentralCrossRef
82.
Fernández-Díaz C, Loricera J, Castañeda S, López-Mejías R, Ojeda-García C, Olivé A, Rodríguez-Muguruza S, Carreira PE, Pérez-Sandoval T, Retuerto M, Cervantes-Pérez EC, Flores-Robles BJ, Hernández-Cruz B, Urruticoechea A, Maíz-Alonso O, Arboleya L, Bonilla G, Hernández-Rodríguez Í, Palma D, Delgado C, Expósito-Molinero R, Ruibal-Escribano A, Álvarez-Rodríguez B, Blanco-Madrigal J, Bernal JA, Vela-Casasempere P, Rodríguez-Gómez M, Fito C, Ortiz-Sanjuán F, Narváez J, Moreno M, López-Corbeto M, Mena-Vázquez N, Aguilera-Cros C, Romero-Yuste S, Ordóñez S, Villa-Blanco I, Gonzélez-Vela MC, Mora-Cuesta V, Palmou-Fontana N, Hernández JL, González-Gay MA, Blanco R (2018) Abatacept in patients with rheumatoid arthritis and interstitial lung disease: a national multicenter study of 63 patients. Semin Arthritis Rheum 48:22–27PubMedCrossRef
83.
Fui A, Bergantini L, Selvi E et al (2019) Rituximab therapy in interstitial lung disease associated with rheumatoid arthritis. Intern Med J 9
84.
Md Yusof MY, Kabia A, Darby M, Lettieri G, Beirne P, Vital EM, Dass S, Emery P (2017) Effect of rituximab on the progression of rheumatoid arthritis-related interstitial lung disease: 10 years’ experience at a single centre. Rheumatology (Oxford) 56:1348–1357CrossRef
85.
Hadjinicolaou AV, Nisar MK, Parfrey H, Chilvers ER, Ostor AJK (2012) Non-infectious pulmonary toxicity of rituximab: a systematic review. Rheumatology (Oxford) 51:653–662CrossRef
86.
87.
Chang HK, Park W, Ryu DS (2002) Successful treatment of progressive rheumatoid interstitial lung disease with cyclosporine: a case report. J Korean Med Sci 17:270–273PubMedPubMedCentralCrossRef
88.
Wallace B, Vummidi D, Khanna D (2016) Management of connective tissue diseases associated interstitial lung disease: a review of the published literature. Curr Opin Rheumatol 28:236–245PubMedPubMedCentralCrossRef
89.
Tashkin DP, Roth MD, Clements PJ, Furst DE, Khanna D, Kleerup EC, Goldin J, Arriola E, Volkmann ER, Kafaja S, Silver R, Steen V, Strange C, Wise R, Wigley F, Mayes M, Riley DJ, Hussain S, Assassi S, Hsu VM, Patel B, Phillips K, Martinez F, Golden J, Connolly MK, Varga J, Dematte J, Hinchcliff ME, Fischer A, Swigris J, Meehan R, Theodore A, Simms R, Volkov S, Schraufnagel DE, Scholand MB, Frech T, Molitor JA, Highland K, Read CA, Fritzler MJ, Kim GHJ, Tseng CH, Elashoff RM, Sclerodema Lung Study II Investigators (2016) Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease [SLS II]: a randomised controlled, double-blind, parallel group trial. Lancet Respir Med 4:708–719PubMedPubMedCentralCrossRef
90.
Wu C, Lin H, Zhang X (2019) Inhibitory effects of pirfenidone on fibroblast to myofibroblast transition in rheumatoid arthritis-associated interstitial lung disease via the downregulation of activating transcription factor 3 [ATF3]. Int Immunopharmacol 74:105700PubMedCrossRef
91.
Solomon JJ, Danoff SK, Goldberg HJ et al (2019) Trail network. The design and rationale of the Trail1 trial: a randomized double-blind phase 2 clinical trial of Pirfenidone in rheumatoid arthritis-associated interstitial lung disease. Adv Ther 36:3279–3287PubMedCrossRef
Metadata
Title
Rheumatoid arthritis–associated interstitial lung disease: an overview of epidemiology, pathogenesis and management
Authors
Yujie Dai
Weina Wang
Yikai Yu
Shaoxian Hu
Publication date
01-04-2021
Publisher
Springer International Publishing
Published in
Clinical Rheumatology / Issue 4/2021
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-020-05320-z

Other articles of this Issue 4/2021

Clinical Rheumatology 4/2021 Go to the issue

Original Article

Prevalent vertebral fractures incur high risk of future fractures in inflammatory myositis

Original Article

Non-radiographic axial spondyloarthritis in Tunisia: main characteristics and detailed comparison with ankylosing spondylitis

Original Article

Things left unsaid: important topics that are not discussed between patients with systemic sclerosis, their carers and their healthcare professionals—a discourse analysis

Original Article

Combined diabetes and arthritis are associated with declined gait speed

Original Article

Enthesitis may be one of the signs of severe disease in familial Mediterranean fever

Case Based Review

Myocarditis and intracardiac thrombus due to Henoch-Schönlein purpura: case report and literature review
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits